Enclomiphene Citrate Cost in Kansas 2026

What Is Enclomiphene Citrate and Why Is It Prescribed?

Enclomiphene citrate is the trans-isomer of clomiphene, prescribed off-label in the United States to restore endogenous testosterone production in men with secondary hypogonadism. Unlike exogenous testosterone replacement therapy, enclomiphene stimulates the hypothalamic-pituitary-gonadal axis, which means it can raise serum testosterone while preserving sperm production. That single pharmacological distinction makes it a common choice for younger men, athletes, or men who want to maintain fertility.

Clomiphene citrate, the racemic parent compound, has been FDA-approved since 1967 for female ovulatory dysfunction. Androxal (enclomiphene citrate), the purified trans-isomer developed by Repros Therapeutics, received a Complete Response Letter from the FDA in 2013 and again in 2016 and never reached the U.S. commercial market as a standalone approved product. [1] Prescribers in Kansas therefore rely entirely on compounded formulations sourced through state-licensed 503A pharmacies or on racemic clomiphene used off-label for men.

The endocrine mechanism is well-characterized. Enclomiphene blocks estrogen receptors at the hypothalamus, which removes negative feedback and drives GnRH pulsatility, triggering LH and FSH release. LH and FSH then stimulate Leydig and Sertoli cells to produce testosterone and support spermatogenesis. [2] In a randomized controlled trial by Kim et al. (BJU Int, 2016; N=124), enclomiphene 12.5 mg daily raised mean serum testosterone from 228 ng/dL to 412 ng/dL at 12 weeks, compared with no meaningful change in the testosterone gel arm, while sperm concentrations remained significantly higher in the enclomiphene group (P<0.001). [2]

Secondary hypogonadism affects roughly 2.1% of adult men across all age groups, according to the European Male Aging Study, though prevalence climbs substantially in men with obesity or type 2 diabetes. [3] Kansas-specific epidemiological breakdowns are not publicly reported, but given that Kansas adult obesity prevalence sits at 36.6% per CDC 2023 data, a meaningful share of men in the state are at elevated risk for secondary hypogonadism. [4]

Enclomiphene Citrate Prices in Kansas in 2026

The most practical price point in Kansas is approximately $90 per month for compounded enclomiphene citrate from a licensed 503A pharmacy. This figure assumes a standard 25 mg once-daily capsule or 12.5 mg once-daily dose depending on the prescriber's titration protocol. No FDA-approved commercial product exists at retail chains such as Walgreens, CVS, or HyVee pharmacy locations in Wichita, Topeka, or Kansas City.

Several variables shift that $90 baseline. Pharmacy markup policies vary. Capsule versus tablet formulation changes manufacturing cost. Some compounding pharmacies include a dispensing fee or a required telehealth consultation charge that raises the all-in monthly spend to $120 to $150 when bundled with a platform subscription. Men obtaining prescriptions through a local Kansas endocrinologist or urologist may pay separately for the office visit (typically $150 to $350 without insurance) and then fill the compound at a separate pharmacy.

The FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act requires that compounded drugs be prepared by a licensed pharmacist or physician and dispensed pursuant to a valid patient-specific prescription. [5] Kansas pharmacies operating under 503A may legally compound enclomiphene because it is not currently on the FDA's Difficult to Compound list and no commercially identical approved product is available. [5] That legal basis keeps Kansas-based compounders operating without restriction as of early 2025.

For context, generic clomiphene citrate 50 mg tablets (the racemic mixture that includes both the cis and trans isomers) can cost as little as $15 to $30 per month at retail in Kansas, per GoodRx data. Some prescribers choose clomiphene over compounded enclomiphene solely on cost when fertility preservation is less time-sensitive, though research published in the Journal of Clinical Endocrinology and Metabolism suggests the zuclomiphene (cis) isomer may contribute to side effects such as visual disturbances and mood changes that the trans-isomer alone avoids. [6]

The HealthRX clinical team uses a three-tier cost framework for Kansas patients considering enclomiphene:

Tier 1 (lowest cost, $15-30/month): Generic racemic clomiphene 25 mg to 50 mg daily, appropriate when fertility preservation is the primary goal and the patient can tolerate potential cis-isomer side effects.

Tier 2 (moderate cost, $90/month): Compounded enclomiphene 12.5 mg to 25 mg daily from a Kansas-licensed 503A pharmacy, appropriate when the clinician wants to minimize estrogenic side effects and the patient's baseline testosterone is below 300 ng/dL.

Tier 3 (highest cost, $120-150/month all-in): Compounded enclomiphene via a telehealth platform with bundled labs and monthly clinical review, appropriate when the patient lacks a local prescriber or wants integrated hormone monitoring.

Kansas Medicaid Coverage for Enclomiphene Citrate

Kansas Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The Kansas Division of Health Care Finance publishes a Preferred Drug List (PDL) that categorizes testosterone replacement agents; enclomiphene appears nowhere on that list, and off-label compounded drugs are categorically excluded from KanCare (the managed care organization model through which most Kansas Medicaid services are delivered). The KanCare formulary management framework prioritizes FDA-approved agents for covered indications, meaning a compounded off-label drug faces no realistic coverage pathway. [7]

Testosterone replacement therapy itself occupies a gray zone under Kansas Medicaid. FDA-approved testosterone formulations (AndroGel, Testim, Axiron, Aveed) may be covered for documented primary hypogonadism with appropriate ICD-10 coding (E29.1), but secondary hypogonadism driven by functional causes such as obesity or metabolic syndrome is harder to demonstrate as medically necessary under standard prior authorization criteria. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends biochemical confirmation with at least two morning total testosterone measurements below 300 ng/dL before initiating any therapy, a bar that Medicaid PA reviewers often require documented evidence of. [8]

For Kansas patients on KanCare who cannot afford out-of-pocket costs, the most realistic option is a referral to a state urology or endocrinology clinic where racemic clomiphene (covered under some plans as an ovulation induction agent, though coded differently for men) might be prescribed at lower cost. That pathway requires careful provider documentation of the off-label indication.

Private Insurance Coverage in Kansas

Private insurance coverage for enclomiphene citrate in Kansas is nearly nonexistent for the same structural reason that blocks Medicaid: no FDA-approved product exists in this indication. Insurers including BCBS of Kansas, Aetna, Cigna, and UnitedHealthcare typically exclude compounded drugs from formularies unless the patient has a documented allergy or intolerance to a commercially available therapeutic equivalent.

The American Urological Association's 2018 guideline on evaluation and management of testosterone deficiency classifies clomiphene-class agents as a treatment option specifically for men desiring to maintain fertility, and some insurers have begun to recognize this clinical distinction. [9] A prescriber willing to submit a detailed letter of medical necessity, including morning testosterone values, LH/FSH results confirming secondary (rather than primary) hypogonadism, and a fertility-preservation rationale, may achieve approval for the underlying compounding supply cost in roughly 10% to 20% of commercial plan appeals based on pharmacy benefit manager data, though this figure is not yet systematically published.

If prior authorization is denied, patients retain the right to file a standard external appeal under the Kansas Insurance Department process. Kansas law aligns with the federal Affordable Care Act's external review requirements, giving patients access to an independent review organization within 45 business days of an adverse determination. The ACA external review standard applies to all non-grandfathered group health plans. [10]

Compounded Enclomiphene Citrate: Kansas-Specific Legality

Compounded enclomiphene citrate is legal in Kansas when dispensed by a state-licensed 503A pharmacy pursuant to a valid prescription from a licensed prescriber. No Kansas state law singles out enclomiphene for additional restriction beyond standard compounding regulations. The Kansas State Board of Pharmacy enforces compliance with both state pharmacy practice acts and the federal DQSA (Drug Quality and Security Act of 2013), which governs 503A compounders. The Kansas State Board of Pharmacy publishes its licensed-compounder list online, allowing patients to verify any dispensing pharmacy. [11]

503B outsourcing facilities, which produce larger batch quantities without individual prescriptions, are federally registered rather than state-licensed. They supply primarily to hospitals and clinics rather than directly to patients, but a Kansas prescriber may order enclomiphene from a registered 503B facility for office dispensing if the facility includes enclomiphene in its formulary.

The FDA's 2023 updated guidance on bulk drug substances for 503A compounding clarifies that a bulk active pharmaceutical ingredient may be used in a 503A compound if the drug appears on a specific positive list or if there is a valid clinical need in the absence of an FDA-approved equivalent. [12] Enclomiphene citrate currently qualifies under that second criterion because no approved equivalent is marketed in the United States.

Patients receiving compounded enclomiphene should confirm that the dispensing pharmacy holds both a Kansas pharmacy license and a current DEA registration, and they should request a Certificate of Analysis for each batch, which reputable 503A compounders provide as standard practice. The USP Chapter 795 standards for non-sterile compounding govern the quality testing requirements these certificates must reflect. [13]

Telehealth Prescribing of Enclomiphene in Kansas

Telehealth prescribing of enclomiphene citrate is fully legal in Kansas as of 2025. Kansas enacted telehealth parity legislation in 2021 (SB 286), and prescribers licensed in Kansas may evaluate, diagnose, and prescribe for male hypogonadism via synchronous video or asynchronous platforms after establishing a valid patient-provider relationship. A Kansas-licensed clinician must sign every prescription; an out-of-state prescriber without Kansas licensure cannot legally prescribe to Kansas patients even through a national telehealth platform.

Several national hormone-health platforms operate with Kansas-licensed clinicians. The typical workflow involves an online intake, a home blood draw ordered through a CLIA-certified lab (LabCorp or Quest Diagnostics, both with Kansas locations), and a video consultation to review results. The American Telemedicine Association's 2023 clinical practice recommendations note that testosterone-related conditions are among the most common hormone disorders managed via telehealth, with patient satisfaction scores above 4.2 out of 5 in published surveys. [14]

Lab costs are a real addition to the monthly spend. A baseline male hormone panel (total testosterone, free testosterone, LH, FSH, SHBG, estradiol, CBC, CMP) runs $75 to $200 at a Kansas LabCorp draw site without insurance. Quest Diagnostics' male hormone panels published reference intervals for testosterone that align with the Endocrine Society's 300 ng/dL threshold for treatment initiation. [15] Follow-up labs at 6 to 12 weeks add additional cost that patients should budget when comparing telehealth platform pricing to in-office care.

How to Minimize Cost in Kansas

The cheapest legal path to enclomiphene in Kansas combines three steps. First, obtain labs through a direct-to-consumer lab service (LabCorp OnDemand or Ulta Lab Tests) at $40 to $75 rather than through a platform bundle. Second, schedule a single telehealth visit with a Kansas-licensed prescriber ($50 to $100 for a focused hormone consult at some platforms). Third, fill the prescription at a Kansas 503A compounding pharmacy that does not charge a dispensing platform fee.

That sequence can reduce all-in monthly costs to approximately $110 to $130 in month one (including labs) and $90 to $95 in subsequent months once baseline labs are established and only quarterly monitoring labs are needed.

GoodRx coupons and manufacturer savings cards do not apply to compounded enclomiphene because it lacks an NDC number. [16] Some compounding pharmacies offer loyalty pricing for three-month or six-month prepaid supplies, reducing the per-month cost to $75 to $80 at select Kansas-based compounders. Patients should ask explicitly whether prepay discounts are available before agreeing to month-to-month billing.

For patients whose financial barrier is acute, the NAFC Patient Assistance directory and some county-based Kansas health departments offer sliding-scale endocrinology consultations that can generate a valid prescription at minimal cost, after which the patient fills the compound independently. [17]

Monitoring and Clinical Expectations in Kansas

Starting enclomiphene without establishing a monitoring protocol wastes both money and clinical opportunity. The Endocrine Society's 2018 male hypogonadism guideline recommends checking total testosterone 3 to 6 months after initiating therapy, then annually once stable. [8] For enclomiphene specifically, LH and FSH should also be checked at the first follow-up visit to confirm the axis is responding; a flat LH response despite dose escalation suggests primary rather than secondary hypogonadism and means enclomiphene is unlikely to work.

Typical response timelines in clinical practice mirror the Kim et al. data: measurable testosterone increases appear by week 4 to 6, with the majority of the effect established by week 12. [2] Men who do not reach 400 ng/dL by week 12 at 25 mg daily should have their diagnosis reassessed. Persistent low testosterone despite an elevated LH warrants referral to a Kansas urologist or reproductive endocrinologist for testicular evaluation.

Estradiol monitoring matters. Enclomiphene blocks hypothalamic estrogen receptors, but peripheral aromatization continues. Some men develop elevated estradiol (>42 pg/mL by LC-MS/MS) on enclomiphene, particularly those with BMI above 30. The Journal of Clinical Endocrinology and Metabolism published data showing that clomiphene-class agents can raise estradiol 20% to 40% from baseline in obese men. [6] Kansas prescribers managing patients with BMI >30 may consider co-prescribing a low-dose aromatase inhibitor if symptomatic estrogen excess develops, though that adds a second compound and additional cost.

Hematocrit should be checked at baseline and at 3 months. Enclomiphene is less likely than injectable testosterone to drive erythrocytosis, but FDA labeling for testosterone products warns of polycythemia risk whenever testosterone rises substantially. [1] A hematocrit above 54% warrants dose reduction or temporary discontinuation per standard practice.

Kansas Prescribers Who Manage Enclomiphene

No Kansas-specific prescriber database publicly identifies clinicians who routinely prescribe enclomiphene. The most reliable routes are board-certified urologists with a men's health subspecialty interest, reproductive endocrinologists at academic centers (University of Kansas Medical Center in Kansas City, KS), or endocrinologists with a focus on male reproductive health. Primary care physicians licensed in Kansas can legally prescribe enclomiphene but may be less familiar with dosing titration and monitoring schedules.

The American Urological Association 2018 guideline explicitly recognizes selective estrogen receptor modulators (SERMs) as a treatment category for testosterone deficiency in men who wish to preserve fertility, giving clinical cover to prescribers willing to write the off-label compound. [9] Showing this guideline language to a hesitant Kansas PCP may remove a barrier to getting a prescription written locally.

If no local prescriber is available or willing, a national telehealth platform with a Kansas-licensed clinician remains the clearest path, as detailed in the telehealth section above.